Effects of serotonin 5-HT3 receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats

European Journal of Pharmacology

Volumn 587, Issue 1-3, 2008, Pages 281-284

  Hirata, Takuya ^a   Keto, Yoshihiro ^a   Nakata, Mari ^a   Takeuchi, Asako ^a   Funatsu, Toshiyuki ^a   Akuzawa, Shinobu ^a   Sasamata, Masao ^a   Miyata, Keiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

(Rat); 5 HT3 receptor antagonist; Abnormal defecation; Colonic water transport; CRF

Indexed keywords

ALOSETRON; CILANSETRON; CORTICOTROPIN RELEASING FACTOR; LOPERAMIDE; RAMOSETRON; SEROTONIN 3 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON ABSORPTION; CONTROLLED STUDY; DEFECATION DISORDER; DOSE RESPONSE; DRUG POTENCY; EXPERIMENTAL MODEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; WATER ABSORPTION; WATER TRANSPORT;

ANIMALS; ANTIDIARRHEALS; BENZIMIDAZOLES; CARBAZOLES; CARBOLINES; COLON; CORTICOTROPIN-RELEASING HORMONE; DEFECATION; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENTRICULAR; LOPERAMIDE; MALE; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; WATER;

EID: 44149102386     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.03.040     Document Type: Article

References (24)

1. Andresen V., Camilleri M., Busciglio I.A., Grudell A., Burton D., McKinzie S., Foxx-Orenstein A., Kurtz C.B., Sharma V., Johnston J.M., Currie M.G., and Zinsmeister A.R. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133 (2007) 761-768
2. Awouters F., Megens A., Verlinden M., Schuurkes J., Niemegeers C., and Janssen P.A. Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig. Dis. Sci. 38 (1993) 977-995
3. Berridge M.J. A general survey of the mechanism and control of intestinal fluid transport. Scand. J. Gastroenterol. Suppl. 18 (1983) 43-49
4. Burdick S., Cui N., Empey L.R., and Fedorak R.N. Vitamin E prevents cold wrap restraint stress-induced intestinal fluid transport alterations in rats. Can. J. Gastroenterol. 8 (1994) 417-421
5. Camilleri M., Bharucha A.E., Ueno R., Burton D., Thomforde G.M., Baxter K., McKinzie S., and Zinsmeister A.R. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am. J. Physiol.: Gasterointest. Liver Physiol. 290 (2006) G942-G947
6. Camilleri M., Northcutt A.R., Kong S., Dukes G.E., McSorley D., and Mangel A.W. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355 (2000) 1035-1040
7. Cann P.A., Read N.W., Holdsworth C.D., and Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig. Dis. Sci. 29 (1984) 239-247
8. Caras S., Krause G., Biesheuvel E., and Steinborn C. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States Study. Gastroenterology 120 (2001) A217
9. Crowell M.D. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br. J. Pharmacol. 141 (2004) 1285-1293
10. Empey L.R., and Fedorak R.N. Effect of misoprostol in preventing stress-induced intestinal fluid secretion in rats. Prostaglandins Leukot. Essent. Fatty Acids 38 (1989) 43-48
11. Funatsu T., Takeuchi A., Hirata T., Keto Y., Akuzawa S., and Sasamata M. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. Eur. J. Pharmacol. 573 (2007) 190-195
12. Grundy D., Al-Chaer E.D., Aziz Q., Collins S.M., Ke M., Tache Y., and Wood J.D. Fundamentals of neurogastroenterology: basic science. Gastroenterology 130 (2006) 1391-1411
13. Hirata T., Keto Y., Funatsu T., Akuzawa S., and Sasamata M. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J. Pharmacol. Sci. 104 (2007) 263-273
14. 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol. Ther. 14 (2000) 775-782
15. Kiso T., Ito H., and Miyata K. Effect of ramosetron on short-circuit current response in rat colonic mucosa. Eur. J. Pharmacol. 320 (1997) 187-192
16. 3 receptor agonist, YM-31636, increases gastrointestinal motility without increasing abdominal pain. Eur. J. Pharmacol. 431 (2001) 35-41
17. 3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Jpn. J. Pharmacol. 86 (2001) 281-288
18. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., and Spiller R.C. Functional bowel disorders. Gastroenterology 130 (2006) 1480-1491
19. 3 receptor in CRH-induce defecation in rats. Am. J. Physiol. 274 (1998) G827-G831
20. 3 receptors in conscious rats. Am. J. Physiol. 292 (2007) G1037-G1044
21. Nishiwaki H., Saitoh N., Nishio H., Takeuch T., and Hata F. Possible role of potassium channels in mu-receptor-mediated inhibition and muscarinic autoinhibition in acetylcholine release from myenteric plexus of guinea pig ileum. Jpn. J. Pharmacol. 82 (2000) 343-349
22. Reynolds I.J., Gould R.J., and Snyder S.H. Loperamide: blockade of calcium channels as a mechanism for antidiarrheal effects. J. Pharmacol. Exp. Ther. 231 (1984) 628-632
23. Spiller R. Role of motility in chronic diarrhoea. Neurogastroenterol. Motil. 18 (2006) 1045-1055
24. 1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br. J. Pharmacol. 141 (2004) 1321-1330